Trial Profile
A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose Ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Applications of Delgocitinib Cream 1, 3, 8, 20 mg/g for 8 Weeks in Adult Subjects With Mild to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2021
Price :
$35
*
At a glance
- Drugs Delgocitinib (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors LEO Pharma
- 29 Jun 2020 Status changed from active, no longer recruiting to completed.
- 02 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.